Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Gloria Niquette

Nurse Practitioner Lake Butler, FL Nurse Practitioner

NPI 1366874174 CMS profile 11074022

155 Se 6Th Pl, Lake Butler, FL 32054

Open in the dashboard

General payments

$7,884

402 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gloria Niquette of Lake Butler, FL is reported in the CMS Open Payments database as having received $7,884 across 402 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,682 73
2024 General $1,547 74
2023 General $1,152 63
2022 General $1,231 64
2021 General $2,273 128

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gloria Niquette
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Gloria Niquette were reported at $1,682. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Gloria Niquette Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $2,273 $135 $40–$426 $132
2022 $1,231 $152 $48–$470 $149
2023 $1,152 $166 $54–$529 $160
2024 $1,547 $173 $55–$556 $164
2025 $1,682 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,127 126 payments
  2. AstraZeneca Pharmaceuticals LP $1,164 29 payments
  3. Novo Nordisk Inc $866 43 payments
  4. Lilly USA, LLC $691 43 payments
  5. Avanir Pharmaceuticals, Inc. $385 23 payments
  6. ITI, Inc. $364 15 payments
  7. Biohaven Pharmaceuticals, Inc. $337 3 payments
  8. Sanofi-Aventis U.S. LLC $260 17 payments
  9. Pfizer Inc. $202 11 payments
  10. Amarin Pharma Inc. $172 15 payments
  11. Other $1,316 77 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,788 400 payments
  2. Education $96 2 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $1,281 69 payments
  2. BREZTRI $567 12 payments
  3. RYBELSUS $554 33 payments
  4. Ozempic $539 33 payments
  5. AIRSUPRA $493 10 payments
  6. VRAYLAR Neuroscience $394 20 payments
  7. NUEDEXTA $385 23 payments
  8. NURTEC ODT $337 3 payments
  9. CAPLYTA $324 13 payments
  10. UBRELVY $316 29 payments
  11. Other $4,009 245 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 105 drugs

Part D claims

4,385

Median for Nurse Practitioner: 389

Drug cost

$457,161

Median for Nurse Practitioner: $21,885

Branded share of claims

18.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 41 $72,344
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 22 $62,271
Eliquis Apixaban Brand 43 $50,651
Jardiance Empagliflozin Brand 35 $49,146
Mounjaro Tirzepatide Brand 29 $42,455
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 28 $37,992
Rybelsus Semaglutide Brand 11 $24,101
Farxiga Dapagliflozin Propanediol Brand 12 $17,160
Myrbetriq Mirabegron Brand 22 $16,792
Repatha Sureclick Evolocumab Brand 19 $16,727

The 10 drugs with the highest cost, of 105 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$52,374

Medicare's payments for the services billed

Medicare patients

177

Average age 73

Services billed

1,200

110 women, 67 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 42%
Chronic kidney disease 41%
Depression 27%
Ischemic heart disease 24%
COPD 21%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $478
$478 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $165
$165 — —
MOUNJARO
  • Lilly USA, LLC $120
$120 29 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $103
$103 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $80
$80 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

402 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record